Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

Market Cap	10.65B +90.2%
Revenue (ttm)	2.21B +24.3%
Net Income	254.51M +773.1%
EPS	0.64 +774.9%
Shares Out	396.81M
PE Ratio	41.87
Forward PE	n/a
Dividend	0.05 (0.19%)
Ex-Dividend Date	Jun 26, 2026

Volume	15,443,561
Open	26.45
Previous Close	26.46
Day's Range	25.55 - 27.23
52-Week Range	13.97 - 35.58
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 2,258
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301246

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 29, 2026

Data Sources Report a data error